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Mendelian disorders of the epigenetic machinery (MDEMs), also named chromatin
modifying disorders, are a broad group of neurodevelopmental disorders, caused
by mutations in functionally related chromatin genes. Mental retardation autosomal
dominant 23 (MRD23) syndrome, due to SETD5 gene mutations, falls into this group of
disorders. KBG syndrome, caused by ANKRD11 gene haploinsufficiency, is a chromatin
related syndrome not formally belonging to this category. We performed high resolution
array CGH and trio-based WES on three molecularly unsolved patients with an initial
KBGS clinical diagnosis. A de novo deletion of 116 kb partially involving SETD5 and
two de novo frameshift variants in SETD5 were identified in the patients. The clinical
re-evaluation of the patients was consistent with the molecular findings, though still
compatible with KBGS due to overlapping phenotypic features of KBGS and MRD23.
Careful detailed expert phenotyping ascertained some facial and physical features that
were consistent with MRD23 rather than KBGS. Our results provide further examples that
loss-of-function pathogenic variants in genes encoding factors shaping the epigenetic
landscape, lead to a wide phenotypic range with significant clinical overlap. We
recommend that clinicians consider SETD5 gene haploinsufficiency in the differential
diagnosis of KBGS. Due to overlap of clinical features, careful and detailed phenotyping
is important and a large gene panel approach is recommended in the diagnostic workup
of patients with a clinical suspicion of KBGS.
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INTRODUCTION
Mendelian disorders of the epigenetic machinery (MDEMs), also known as chromatin modifying
disorders, are an expanding group of neurodevelopmental disorders (NDDs), caused by mutations
in functionally related chromatin regulators (1). These syndromes are characterized by a
significant phenotypic overlap as they share several clinical features including intellectual disability,
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developmental delay, growth retardation, and similar facial
dysmorphisms (2). Interestingly, the phenotypic overlap between
these syndromes appears to reflect the molecular interaction of
chromatin modifiers, acting in common cellular mechanisms
and pathways (3). Over recent years, genome wide analyses
including chromosome microarray (CMA) and whole exome
sequencing (WES) have been successfully utilized for this patient
group to optimize molecular diagnosis and to refine the clinical
phenotyping (4), resulting in MDEMs emerging as one of the
most rapidly expanding groups (1).
KBG syndrome (KBGS, OMIM#148050), although
functionally related, does not formally belong to the MDEMs
group, while the mental retardation autosomal dominant
23 syndrome (MRD23, OMIM#615761) falls into this broad
group of disorders. They are caused by ANKRD11 (Ankyrin
Repeat Domain-Containing Protein 11, OMIM∗611192) gene
haploinsufficiency and SETD5 (Set Domain-Containing Protein
5, OMIM∗615743) gene loss-of-function (LoF) mutations,
respectively (5, 6).
KBGS is a disorder of chromatin-associated transcription
machinery, mainly characterized by neurodevelopmental delay,
macrodontia of the upper central incisors, facial dysmorphism,
short stature, and skeletal anomalies (7). ANKRD11, located
on chromosome 16q24.3, encodes a chromatin regulator of
histone acetylation during neural development (8). The gene
is also able to recruit both histone deacetylases (HDACs) and
histone acetyltransferases (HATs) to promoters regulating the
transcription of target genes (9).
The MRD23 phenotype is characterized by ID, facial
dysmorphisms, skeletal anomalies, behavioral problems and
speech and language difficulties (10). SETD5, located on
chromosome 3p25, encodes for a putative methyltransferase,
and belongs to the “writers” group of epigenetic ID genes
(11). The gene is widely expressed across the brain, where
it regulates gene transcription through its interaction with
the histone deacetylase 3 (HDAC3) and RNA polymerase
II associated factor 1 (PAF1) complexes (12). SETD5 is
also the strongest candidate gene of the 3p25 microdeletion
syndrome, as patients harboring either heterozygous SETD5 LoF
mutations or 3p25 microdeletions spanning SETD5 show an
overlapping phenotype.
SUBJECTS AND METHODS
Patients
In this study, we performed high resolution array CGH and trio-
based WES on three previously molecularly unsolved patients
with an initial suspected diagnosis of KBGS, in order to
detect novel pathogenic variants. Patients underwent clinical
phenotyping by their referring clinical geneticists, and according
to the recently proposed diagnostic aid for KBG syndrome (13),
were compatible with a clinical KBGS diagnosis. This study was
approved by the ethical committee of IRCSS Istituto Auxologico
Italiano, and written informed consent was obtained for each
subject and/or their parents.
High Resolution Array Comparative
Genomic Hybridization (a-CGH) Analysis
High resolution array comparative genomic hybridization (a-
CGH) analysis was performed on genomic blood DNA of
P1, P2, and their parents, using the SurePrint G3 Human
CGH Microarray Kit 2 × 400K in accordance with the
manufacturer’s instructions (Agilent Technologies, Palo Alto,
CA). Data extraction and analysis were performed using Agilent
CytoGenomics v.3.0 (Agilent Technologies, Palo Alto, CA).
Detected copy number variants (CNVs) were classified according
to guidelines reported by Miller et al. (14) and by the American
College of Medical Genetics (15).
Whole Exome Sequencing
For P2, WES was performed on 50 ng of genomic DNA of each
member of the trio (index patient and parents), prepared using
the Agilent SureSelect Clinical Research Exome enrichment kit
(Agilent, Santa Clara, California) that enables the enrichment
of the exonic regions and the splice sites flanking regions
of all human exons, followed by sequencing with 150-bp
paired-end reads on the NextSeq500 platform (Illumina, San
Diego, California).
Reads were mapped to the human genome (hg 19/GRCh37)
using the Burrows-Wheeler Alignment tool (16). The variant
calling was performed with the GATK Haplotype Caller (Broad
Institute, Cambridge, MA) (17). The resulting variant call format
(VCF) files were annotated using the Web ANNOtate VARiation
(wANNOVAR) software (18).
Given the rarity of the suspected disease, the variant list
was filtered according to an allele frequency ≤0.1% according
to gnomAD (http://gnomad.broadinstitute.org/), the ExAC
Browser of Broad Institute (19), and 1000 Genomes database.
Variants were sorted out following both the de novo dominant
and the autosomal recessive inheritance models; the functional
impact, the bioinformatics predictions, and the presence in
OMIM genes were further considered for variants analysis.
For P3, Trio exome sequencing was performed in the
context of a pilot project funded by the Israeli ministry of
health. Sequencing was performed in a CLIA certified laboratory
(Gene by gene, Huston, TX, USA), on a Novaseq6500 platform
(Illumina, San Diego, California) using the Twist Human Core
Exome Kit (Twist, San Francisco, California). Mapping of the
obtained reads to the reference genome (build GRCh37/hg19),
variant calling, annotation, and data analysis were done using
the Genoox data analysis platform Ltd. (Genoox, Palo Alto,
California). We filtered sequencing data on a trio-based
paradigm to identify recessive (homozygous and compound
heterozygous), X-linked, and potential de novo variants in the
proband. Variants were prioritized based on their effect on the
protein and minor allele frequency <1% in general population
databases, such as gnomAD, the Greater Middle-East Variome
(http://igm.ucsd.edu/gme/), and the Rambam Genetics Institute
internal database of over 1,500 Israeli exomes.
Variant clinical classification was performed according to
ACMG classification (20) using the varsome database (21).
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Sanger Sequencing
The pathogenic variants identified by WES analysis were
validated by Sanger Sequencing using the Big-Dye R© Terminator
v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific) and the
Applied Biosystems Abi Prism 3500 Sequencer.
Sequences were then aligned to the human reference genome
sequence (human genome assembly GRCh37/hg19) and analyzed
with the ChromasPro 1.5 software (Technelysium Pty Ltd.,
Tewantin, QLD, Australia). Primers are available upon request.
RESULTS
The clinical features of the three reported patients are detailed in
Table 1. Facial appearances of patients 2 and 3 at evolving ages
(from birth to the age at diagnosis) are shown in Figure 1.
Patient 1 (Table 1) is the first born of non-consanguineous
Italian healthy parents. She was born at term by cesarean section
because of nuchal cord, after an uneventful pregnancy. She
started walking at the age of 16 months and said her first
words before 12 months. She had persistent mild constipation.
She displayed mild intellectual disability (WISC-III: IQ = 70
at the age of 8 years and 9 months) and according to her
parents demonstrated a short attention span. At the age of
9 a neuropsychological evaluation described an inhibited and
immature personality, and she needed a support teacher at
school. At 10 years old she was diagnosed with mild hearing
impairment. She has not had any seizures.
Aged 12 her growth parameters were in the low normal
range (height on the 25th centile, weight on the 3rd centile,
and occipitofrontal circumference on the 10th centile). Her facial
features are similar to KBGS patients, with triangular face, low
hairline, thick eyebrows, broad nasal root and bulbous nasal tip,
long philtrum, and broad incisors. She has long palpebral fissures
with mild asymmetrical ptosis and mild strabismus. She wears
glasses for astigmatism, and she has a nasal vocal quality.
Previous testing included standard karyotyping, FMR1
analysis and ANKRD11 sequencing which were all normal.
High resolution array CGH analysis detected a
de novo 3p25.3 deletion of 116 kb (arr[GRCh37]
3p25.3(9387774_9503839)× 1 dn) involving three Refseq
genes: THUMPD3 (Homo sapiens THUMP domain-containing
3), THUMPD3-AS1 (THUMPD3 antisense RNA 1), and SETD5,
which is partially deleted as the proximal deletion breakpoint
maps within intron 17 (transcript NM_001080517.2) (Figure 2).
According to international guidelines this deletion was classified
as pathogenic.
Patient 2 (Figure 1, Table 1) is the second born child of
non-consanguineous Arab healthy parents. Delivery occurred by
cesarean section at term after an uneventful pregnancy. Soon
after birth, audiological screening revealed a conductive hearing
impairment. Parents report she started sitting at 9 months of age,
crawling at 17 months, and walking without support at the age of
19 months. Her first words started after 1 year of age, but of note
she is bilingual (Italian-Arabic). Dental eruption occurred after
12 months. At the age of 15 months a development assessment
was performed with Griffith’s Scale showing a General Quotient
of Development (GQ) = 86 and a significant deficit in motor
abilities. A new assessment at the age of 27 months showed a
GQ= 80.
We saw the patient for the first time when she was 2 years
old. Physical examination revealed dysmorphic facial features
including a low frontal and posterior hairline, thick eyebrows
with mild synophrys, broad nasal root and bulbous nasal tip,
long philtrum, and anteverted ears (Figures 1B,C). Her growth
parameters were normal, and she has not had any seizures.
She had bilateral surgery at the age of 7 years because
of a bilateral conductive hearing impairment and left stapes
malformation, with apparently good results. She required
surgical removal of deciduous teeth around 10 years old, because
of dental crowding for lack of teeth loss. In the past she wore
orthotic insoles for flat feet.
Patient 2 is now 11 years old and her growth parameters
remain normal (10th−25th centile for height, 50th centile for
weight and 50th−75th centile for occipitofrontal circumference).
She attends school with a support teacher. No problems in
sleep or behavior are reported. She wears glasses for myopia.
Her facial appearance in many ways resembles the facial
features seen in KBGS patients, including broad frontal incisors:
as evident in Figure 1, bulbous nose and thick eyebrows
present since infancy, with a progressively more evident large
nasal root and prominent columella. Her decidual incisors
are not notable, her permanent frontal incisors are large with
accentuated mammelons.
Previous diagnostic testing included NIPBL, SMC1A, SMC3,
HDAC8, RAD21, and ANKRD11 sequencing, low resolution
array-CGH and a FMR1 test which were all negative as was a
high-resolution array CGH.
Trio whole-exome sequencing (proband and parents) revealed
a de novo frameshift deletion in SETD5 (NM_001080517.2).
The variant results in a single nucleotide deletion in exon 9
(c.959delA; p.Lys320AsnfsTer15) and is predicted to result in
a premature stop codon after 15 amino acids (Figure 2). The
alteration maps within the region encoding for the conserved
protein SET domain.
Patient 3 (Figure 1, Table 1) is a 17-year-old male with mild
intellectual disability (IQ= 73) and dysmorphic features.
He is the first born of non-consanguineous Sephardic
Jewish parents. During pregnancy, standard karyotype analysis
was performed by amniocentesis due to increased nuchal
translucency (3.5mm), confirming a normal male 46,XY
chromosome picture. He was born at term with a birth weight of
2,700 g (5th centile). Hypotonia and global developmental delay
were apparent from 5 months of age, and he started to walk at 30
months of age.
Bone age at 6 years was delayed by 2 years. Muscle biopsy
(for a possibility of mitochondrial disorder) and head MRI at 7.5
years old were normal. Physical examination at 16 years of age
(Figures 1J,L,M) noted that he has a triangular face, low anterior
and posterior hairline, synophyrs, long palpebral fissures,
epicanthal folds, low set overfolded ears, anteverted nares, long
philtrum, thin upper lip, macrodontia (Figure 1N), overcrowded
and misplaced teeth, pectus excavatum, genu varus, and flat foot.
Chest radiograph revealed accessory cervical ribs (Figure 1K). As
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TABLE 1 | Clinical features of the three reported patients in comparison with previously reported patients with SETD5 mutations/deletions.
Clinical features PT1 PT2 PT3 Previously
reported cases
(n = 32)a,b,c
Overall
(n = 35)a
Age at evaluation 12y8ms 11y6m 17y
Sex F F M
Pathogenetic variant
(GRCh37)
3p25.3(9387774_9503839)× 1 dn c.959delA;
p.Lys320AsnfsTer15
c.1573_1574delTT;
p.Leu525ArgfsTer17
GROWTH
Height (cm) 146 (10th) 141.3 (10th−25th) 168 (25th)
Weight (kg) 34 (3rd) 42.7 (50th) 45.8 (5th)
OFC (cm) 50.5 (<3rd) 53.5 (50th−75th) 53 (3rd)
Growth retardation N N N 11/29 = 38% 11/32 = 34%
Microcephaly Y N Y 0/28 = 0% 2/31 = 9.5%
Height at birth (cm) 47 (5th) 49 (30th) na
Weight at birth (kg) 2.570 (3rd) 3.490 (65th) 2.700 (5th)
OFC at birth (cm) 32.5 (8th) 32.5 (8th) na
NEUROLOGIC
Developmental delay Y Y Y 26/30 = 87% 29/33 = 88%
Speech delay na na N 23/29 = 79% 23/30 = 77%
Motor delay na Y Y 20/29 = 69% 22/31 = 70%
Intellectual disability Borderline/mild (IQ 70) Borderline (GQ 80) Borderline/mild (IQ 73) 28/30 = 93% 31/33 = 94%
Seizures N N N 3/31 = 10% 3/34 = 9%
ASD N N Y 8/28 = 28.5% 9/31 = 29%
Behavioral abnormalities Short attention span,
inhibition, immaturity
Short attention span,
phobias
N 21/32 = 66% 23/35 = 66%
CRANIOFACIAL DYSMORPHISM
Brachycephaly N N N 4/25 = 16% 4/28 = 14%
Triangular face Y Y Y 6/14 = 43% 9/17 = 53%
Long/smooth and/or
prominent philtrum
Long N Long 19/28 = 68% 21/31 = 68%
Palatal defects Y, narrow palate N N 4/26 = 15% 5/29 = 17%
Micrognathia N Y, mild Y 9/23 = 39% 11/26 = 42%
Low-set/abnormal ears Y Y Y 12/26 = 46% 15/29 = 52%
Hearing loss Y Y N 2/22 = 9% 4/25 = 16%
Palpebral fissures Long Long Long 8/23 = 35% 11/26 = 42%
Synophrys and eyebrow
abnormalities
Large eyebrows Broad bushy eyebrows,
and mild synophrys
Broad bushy eyebrows,
and synophrys
11/25 = 44% 14/28 = 50%
Ptosis Y N N 3/25 = 12% 4/28 = 14%
Anteverted nares Y Y Y 7/24 = 29% 10/27 = 37%
Broad/low nasal bridge and
or abnormal shape
Broad and high prominent
nasal bridge with bulbous
nasal tip
Broad and high
prominent nasal bridge
with bulbous nasal tip
Broad and high
prominent nasal bridge
with bulbous nasal tip
21/26 = 81% 24/29 = 83%
Thin upper lip Y N Y 10/16 = 62.5% 12/19 = 63%
Teeth anomalies Macrodontia, ridged teeth,
malposition of teeth
Macrodontia, ridged
and crowded teeth,
malposition of teeth
Macrodontia, ridged
and crowded teeth,
malposition of teeth
6/29 = 21% 9/32 = 28%
OTHER ANOMALIES
Genitourinary defects N N Cryptorchidism 5/22 = 23% 6/25 = 24%
Leg length discrepancy N N N 3/19 = 16% 3/22 = 14%
Scoliosis, kyphosis, lordosis na N Thoracic kyphosis 9/23 = 39% 10/25 = 40%
Hand anomalies Mild brachydactyly N N 10/26 = 38% 11/29 = 38%
Postaxial polydactyly N N N 7/25 = 28% 7/28 = 25%
Low hairline Anterior Anterior Anterior and posterior 6/21 = 29 % 9/24 = 37.5%
Muscle hypotonia na na Y, in infancy 10/18 = 55.5% 11/19 = 58%
(Continued)
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TABLE 1 | Continued
Clinical features PT1 PT2 PT3 Previously
reported cases
(n = 32)a,b,c
Overall
(n = 35)a
Congenital heart disease N N Y, mitral stenosis 11/28 = 39% 12/31 = 39%
Feeding difficulties N N N 16/24 = 67% 16/27 = 59%
Gastrointestinal or
abdominal wall anomalies
Mild constipation N N 8/22 = 36.5% 9/25 = 36%
aPatients in which the presence or absence of each feature was not reported are not included.
bRauch et al. (22), Grozeva et al. (6), Kuechler et al. (11), Kobayashi et al. (23), Szczałuba et al. (24), Parenti et al. (3), Green et al. (25), Powis et al. (10), and Aoi et al. (26).
cOnly patients with SETD5 loss of function mutations or intragenic deletions are considered.
shown in Figure 1, the facial features became more evident with
growth, in particular, the triangular face and overfolded ears were
less apparent in infancy and childhood. Skeletal disproportion
was confirmed by measurements performed at age 17: upper to
lower segment ratio of 0.85, below the normal ratio (∼1) for his
age, and arm span to height ratio of 1.035 (normal range).
Previous genetic testing included low resolution chromosomal
microarray, ANKRD11 gene sequencing and NGS-based
deletions/duplications analysis, and targeted NGS panel for
Noonan genes. All previous analyses were negative.
A de novo 2 bp deletion in SETD5 (NM_001080517.2) was
detected by WES of the P3 trio. The variant maps within exon
14 (c.1573_1574delTT; p.Leu525ArgfsTer17) and is predicted to
cause the formation of a premature stop codon after 17 amino
acids (Figure 2).
The two identified point mutations are novel and according
to ACMG classification, can be classified as pathogenic since they
fulfill the PVS1, PS2, and PM2 criteria. Both variants have been
confirmed by Sanger sequencing analysis (Figure 2).
DISCUSSION
With the advent of clinical exome sequencing, MDEMs have
emerged as an increasingly expanding group of individually rare
conditions showing partial phenotypic overlap, that collectively
represent a relatively common cause of intellectual disability (1).
Here we report three patients with an initial clinical suspicion
of KBGS, found to harbor SETD5 genetic alterations, using
integrated genome-wide analyses.
In all the three patients the pathogenic mechanism of the
SETD5 alteration is haploinsufficiency. Array CGH analyses
identified in P1 a pathogenic deletion at 3p25.3, involving the
THUMPD3, SETD5, and THUMPD3-AS1 genes. The deletion
overlaps the 3pter-p25 microdeletion syndrome critical region
(OMIM#613792), confirming the crucial role of the above genes
in the phenotype (Figure 2). WES was crucial to reach a
definite molecular diagnosis in P2 and P3, both found to be
carriers of an unreported de novo pathogenic variant within
SETD5. Each variant introduces premature termination codons
into the transcript which is expected to be either degraded by
nonsense mediated decay (NMD) or translated into truncated
dysfunctional proteins.
Our results confirm the importance of CMA and trio-based
WES as diagnostic tools for molecularly unsolved patients.
Following the molecular results, clinical re-evaluation of
the patients was compatible with the diagnosis of 3pter-
p25 microdeletion syndrome (P1) and MRD23 (P2 and
P3) (Table 1), respectively. Detailed cross-comparison of the
overall phenotype of P1, P2, and P3 with the patients
with MRD23 syndrome and small 3p25.3 microdeletions,
described in the literature, pointed out that our three patients
show the major clinical findings of MRD23 and 3pter-p25
microdeletion syndrome, namely ID, developmental delay,
behavioral features, and facial dysmorphisms, in addition to
minor features such as microcephaly, teeth anomalies, and
hearing loss which have been rarely reported in previous patients
(Table 1).
Taking into account the phenotype of our patients vs. that of
already reported ANKRD11 and SETD5 mutated/deleted cases,
a significant clinical overlap between KBGS, MRD23, and the
chromosome 3pter-p25 deletion syndrome can be appreciated
(Table S1). In particular, the cognitive profile ranked as mild
intellectual disability, the developmental delay, and learning
difficulties present in all three patients and Autism Spectrum
disorder (ASD) in P3 and behavioral anomalies in P1 are mostly
shared by all syndromes (Table 1, Table S1). Atrioventricular
septal defects of patient 3, are described in all conditions as
well. Of note, two out of the three patients do not show hand
anomalies consistent with KBGS, which are good diagnostic
clues for differential diagnosis (Table 1, Table S1). Regarding
the facial appearance, the three patients have features that
resemble KBGS. Previous large cohorts of KBGS described
the facial features as not always being “gestalt” or reliable in
some patients. In addition, KBGS expert review of P2 and P3’s
photographs did not conclude a satisfactory resemblance to
KBGS in their facial features and, in addition for patient 3,
with respect to his skeletal proportions. It is therefore important
to recognize that whilst disorder specific diagnostic criteria
have been proposed for individual conditions, these do have
limitations in neurodevelopmental disorders with overlapping
phenotypes. Therefore, it is important in such patients to
undertake comprehensive genomic analyses and to then combine
both the genotype and phenotype information together to reach
an informed conclusion. In conditions such as these where doubt
remains, expert opinion can be helpful in recognizing subtleties
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FIGURE 1 | Clinical features of patients 2 and 3. (A) P2 as an infant and at the age of 2 (B,C), 6 (D,E), and 8 (F,G) years. (A–G) Facial dysmorphisms of P2 evolving
with age include low anterior hairline, thick eyebrows, long palpebral fissures, and bulbous nose. (H) P3 at 12 months, and at the age of 3 (I) and 16 years (J,L–N).
(H–J, L–N) Facial dysmorphisms of P3 evolving with age include triangular face, low anterior, and posterior hairline (L), synophris, long palpebral fissures, anteverted
nares, long philtrum, thin upper lip, low set and overfolded ears, overcrowded, and misplaced teeth (N). Other findings such as pectus excavatum, flat foot, and
slender habitus can be noticed as well (J). (K) P3 chest radiograph revealing accessory cervical ribs.
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FIGURE 2 | Physical map of the 3p25.3 genomic region and detected variants. In the upper part, the physical map of the 3p25.3 genomic region shows the deletion
(red bar) detected in patient 1 and the two SNVs detected in patients 2 and 3. The 3pter-p25 deletion syndrome critical region is indicated by a black bar, the RefSeq
genes are depicted in dark blue, and the OMIM disease genes in green. The image is a modification of a version obtained from the UCSC Genome Browser (human
genome assembly GRCh37/hg19). In the lower part, an array CGH profile shows the 3p25.3 deletion identified in patient 1, and Sanger sequencing confirmation of
the two SNVs detected in patient 2 and patient 3. Genomic positions refer to the human genome assembly GRCh37/hg19.
of the phenotype, which may not be apparent otherwise. This was
true for our patients.
Currently, mutations in both SETD5 and ANKRD11 genes
have been identified in patients with Cornelia de Lange (CdL)
syndrome overlapping phenotypes, resulting in the terminology
of “cohesin-related” syndromes (3, 26, 27). ANKRD11 variants
have also been associated with Coffin-Siris-like syndrome (28),
another syndrome resulting from chromatin dysregulation,
further underlining that mutations in different but functionally
related chromatin-associated factors might result in strongly
overlapping clinical pictures. Our study findings suggest that
SETD5 pathogenic variants, akin to what has already been
observed in CdL-like phenotypes, can cause a phenotypic
spectrum overlapping with KBGS. Interestingly, the ANKRD11
and SETD5 proteins physically interact at the molecular
level as demonstrated by spectrometry assays performed in
mouse embryonic stem cells and mouse neural progenitor
cells (12). Moreover, both proteins interact with HDAC3,
a key regulator of histone acetylation/deacetylation balance
(8, 12).
Whilst there is significant phenotypic overlap between the
above-mentioned conditions, however, they still remain distinct
clinical entities. This is important for long term support to
patients and families, as there are differences and subtleties in
both clinical features and neurodevelopmental profiles between
these conditions which become apparent only when patients are
deeply phenotyped. “Lumping” conditions together is generally
unhelpful and confusing for families and patients.
CONCLUSIONS
In conclusion, the described patients confirm the increasing
occurrence of genotype-driven syndrome recognition for
subtle phenotypes of neurodevelopmental disorders caused by
chromatin-related genes.
The description of our patients increases the number of
reported cases with genomic alterations involving SETD5,
providing novel molecular and clinical information.
We recommend that clinicians consider 3p25 microdeletion
syndrome and/or MRD23 in the differential diagnosis of KBGS,
and that SETD5 should be included in cohesion-related gene
panels in order to expedite molecular diagnoses in these
patient groups.
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